Literature DB >> 27249008

Use of single chain antibody derivatives for targeted drug delivery.

Yaghoub Safdari1,2, Vahideh Ahmadzadeh3,4, Masoumeh Khalili5, Hossein Zarei Jaliani6, Vahid Zarei7, Vahid Erfani-Moghadam1,2.   

Abstract

Single chain antibodies (scFvs), which contain only the variable domains of full-length antibodies, are relatively small molecules that can be used for selective drug delivery. In this review, we display how scFv antibodies help improve the specificity and efficiency of drugs. Small interfering RNA (siRNA) delivery using scFv-drug fusion peptides, siRNA delivery using scFv-conjugated nanoparticles, targeted delivery using scFv-viral peptide- fusion proteins, use of scFv in fusion with cell penetrating peptides for effective targeted drug delivery, scFv-mediated targeted delivery of inorganic nanoparticles, scFv-mediated increase of tumor killing activity of granulocytes, use of scFv for tumor imaging, site-directed conjugation of scFv molecules to drug carrier systems, use of scFv to relieve pain, use of scFv for increasing drug loading efficiency are among the topics that are discussed here.

Entities:  

Keywords:  Immunoliposome; fusion peptide; nanoparticle; scFv; targeted drug delivery

Year:  2016        PMID: 27249008      PMCID: PMC5023511          DOI: 10.2119/molmed.2016.00043

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  80 in total

1.  Novel single-chain Fv' formats for the generation of immunoliposomes by site-directed coupling.

Authors:  Sylvia K E Messerschmidt; Anke Kolbe; Dafne Müller; Michael Knoll; Jürgen Pleiss; Roland E Kontermann
Journal:  Bioconjug Chem       Date:  2007-11-08       Impact factor: 4.774

Review 2.  Central role of dendritic cells in the regulation and deregulation of immune responses.

Authors:  F Granucci; I Zanoni; P Ricciardi-Castagnoli
Journal:  Cell Mol Life Sci       Date:  2008-06       Impact factor: 9.261

3.  The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP.

Authors:  Cai-Hong Yun; Kristen E Mengwasser; Angela V Toms; Michele S Woo; Heidi Greulich; Kwok-Kin Wong; Matthew Meyerson; Michael J Eck
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-28       Impact factor: 11.205

Review 4.  Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution.

Authors:  Marina A Dobrovolskaia; Parag Aggarwal; Jennifer B Hall; Scott E McNeil
Journal:  Mol Pharm       Date:  2008-05-30       Impact factor: 4.939

5.  Activation of epithelial CD98 glycoprotein perpetuates colonic inflammation.

Authors:  Torsten Kucharzik; Andreas Lugering; Yutao Yan; Adel Driss; Laetitia Charrier; Shanthi Sitaraman; Didier Merlin
Journal:  Lab Invest       Date:  2005-07       Impact factor: 5.662

Review 6.  Cellular and molecular mechanisms of fibrosis.

Authors:  T A Wynn
Journal:  J Pathol       Date:  2008-01       Impact factor: 7.996

7.  MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Authors:  Jeffrey A Engelman; Kreshnik Zejnullahu; Tetsuya Mitsudomi; Youngchul Song; Courtney Hyland; Joon Oh Park; Neal Lindeman; Christopher-Michael Gale; Xiaojun Zhao; James Christensen; Takayuki Kosaka; Alison J Holmes; Andrew M Rogers; Federico Cappuzzo; Tony Mok; Charles Lee; Bruce E Johnson; Lewis C Cantley; Pasi A Jänne
Journal:  Science       Date:  2007-04-26       Impact factor: 47.728

Review 8.  Prolyl 4-hydroxylases, key enzymes in the synthesis of collagens and regulation of the response to hypoxia, and their roles as treatment targets.

Authors:  Johanna Myllyharju
Journal:  Ann Med       Date:  2008       Impact factor: 4.709

9.  Regulation of alternative macrophage activation by galectin-3.

Authors:  Alison C MacKinnon; Sarah L Farnworth; Philip S Hodkinson; Neil C Henderson; Kirsten M Atkinson; Hakon Leffler; Ulf J Nilsson; Christopher Haslett; Stuart J Forbes; Tariq Sethi
Journal:  J Immunol       Date:  2008-02-15       Impact factor: 5.422

Review 10.  Drug delivery and nanoparticles:applications and hazards.

Authors:  Wim H De Jong; Paul J A Borm
Journal:  Int J Nanomedicine       Date:  2008
View more
  11 in total

1.  Dopamine D2 and Serotonin 5-HT1A Dimeric Receptor-Binding Monomeric Antibody scFv as a Potential Ligand for Carrying Drugs Targeting Selected Areas of the Brain.

Authors:  Agata Kowalik; Mateusz Majerek; Krzysztof Mrowiec; Joanna Solich; Agata Faron-Górecka; Olga Woźnicka; Marta Dziedzicka-Wasylewska; Sylwia Łukasiewicz
Journal:  Biomolecules       Date:  2022-05-26

2.  Different expression systems resulted in varied binding properties of anti-paclitaxel single-chain variable fragment antibody clone 1C2.

Authors:  Gorawit Yusakul; Seiichi Sakamoto; Poomraphie Nuntawong; Hiroyuki Tanaka; Satoshi Morimoto
Journal:  J Nat Med       Date:  2017-10-12       Impact factor: 2.343

3.  Anti-Proliferative Effect of Specific Anti-EGFR Single Chain Antibody on Triple Negative Breast Cancer Cells.

Authors:  Forough Abdollahzadeh; Foroogh Nejatollahi
Journal:  Rep Biochem Mol Biol       Date:  2020-07

4.  Targeting HER2-breast tumors with scFv-decorated bimodal nanoprobes.

Authors:  Christophe Alric; Katel Hervé-Aubert; Nicolas Aubrey; Souad Melouk; Laurie Lajoie; William Même; Sandra Même; Yann Courbebaisse; Anastasia A Ignatova; Alexey V Feofanov; Igor Chourpa; Emilie Allard-Vannier
Journal:  J Nanobiotechnology       Date:  2018-02-21       Impact factor: 10.435

5.  Purification and Characterization of Antibodies in Single-Chain Format against the E6 Oncoprotein of Human Papillomavirus Type 16.

Authors:  F Verachi; Z Percario; P Di Bonito; E Affabris; C Amici; L Accardi
Journal:  Biomed Res Int       Date:  2018-05-20       Impact factor: 3.411

6.  Statistical optimization of culture conditions for expression of recombinant humanized anti-EpCAM single-chain antibody using response surface methodology.

Authors:  Aidin Behravan; Atieh Hashemi
Journal:  Res Pharm Sci       Date:  2021-03-05

Review 7.  Recent Advances in the Surface Functionalization of PLGA-Based Nanomedicines.

Authors:  Mazen M El-Hammadi; José L Arias
Journal:  Nanomaterials (Basel)       Date:  2022-01-22       Impact factor: 5.076

8.  An E. coli-produced single-chain variable fragment (scFv) targeting hepatitis B virus surface protein potently inhibited virion secretion.

Authors:  Cheng Li; Yang Wang; Tiantian Liu; Matthias Niklasch; Ke Qiao; Sarah Durand; Li Chen; Mifang Liang; Thomas F Baumert; Shuping Tong; Michael Nassal; Yu-Mei Wen; Yong-Xiang Wang
Journal:  Antiviral Res       Date:  2018-12-30       Impact factor: 10.103

9.  ScFvs as Allosteric Inhibitors of VEGFR-2: Novel Tools to Harness VEGF Signaling.

Authors:  Kurt Ballmer-Hofer; Caroline A C Hyde; Thomas Schleier; Dragana Avramovic
Journal:  Int J Mol Sci       Date:  2018-05-01       Impact factor: 5.923

Review 10.  Paving the Road for RNA Therapeutics.

Authors:  Niels Dammes; Dan Peer
Journal:  Trends Pharmacol Sci       Date:  2020-09-03       Impact factor: 14.819

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.